ArticleJournal of hepatocellular carcinoma2026
TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From anatomical to biological resectability: navigating adaptive resistance in hepatocellular carcinoma conversion.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with BCLC stage B or C hepatocellular carcinoma (HCC) often face long waiting times. The effectiveness of different tumor control strategies remains unclear. This study evaluates preoperative conversion therapies for liver transplantation (LT). Methods: This study retrospectively analyzed 269 patients with HCC at BCLC stage B or C from a single center from January 2015 to August 2024. All these patients underwent liver transplantation. They were divided into three groups by treatment: transcatheter arterial chemoembolization (TACE) (n = 150), TACE + tyrosine kinase inhibitor (TKI) (n = 74), and TACE + TKI+immune checkpoint inhibitors (ICI) (n = 45). Preoperative assessments included blood tests, liver and kidney function, coagulation, tumor markers, and imaging to evaluate tumor response and monitor adverse events. Data collected included baseline characteristics, lab results, surgical details, preoperative treatment response, adverse events, 1-year survival, tumor-free survival, and donor information. Results: Baseline characteristics were well-balanced across the three groups. The TACE + TKI + ICI group showed higher DCR, ORR, and CRR than both the TACE-alone and TACE + TKI groups (all P < 0.05; χ Conclusion: In the conversion therapy of HCC, the combination of TACE + TKI + ICI has demonstrated higher efficacy, longer recurrence-free survival, manageable safety, and does not interfere with subsequent LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.